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To identify determinants of medication adherence among patients with type 2 diabetes based on the health action
process approach. This cross-sectional study was conducted among 734 patients with type 2 diabetes attending to
south Tehran health centers during June to December 2018. Data were gathered using the Morisky Medication
Adherence Scale (MMAS-8-Item) and the health action process approach questionnaire. We used Mann-Whitney,
Pearson Chi-Squared, Fisher's Exact and Independent Samples Tests for comparison of adherence medication by
demographic characteristics; and linear regression analysis to predict factors related to medication adherence
based on HAPA. P-value less than 0.05 considered statistically significant. A total of 232 men and 502 women
participated in the study, Mean age was 61.61  9.74. Most participants (82.3%) reported low medication
adherence (females: 68.4%). Medication adherence was significantly associated with gender (p ¼ 0.03). Medi-
cation adherence was significantly predicted by intention (β ¼ 0.172, p ¼ 0.0001), task self-efficacy (β ¼ 0.172, p
¼ 0.01), copping planning (β ¼ 0.6, p ¼ 0.0001) and copping self-efficacy (β ¼ -0.244, p ¼ 0.001). The level of
adherence to medications among type 2 diabetes patients was low. The behavior intention, task self-efficacy,
copping planning and copping self-efficacy were significant determinants contributed to the medication adher-
ence. HAPA inventory includes various factors, especially types of self-efficacy. Thus, utilization of this
comprehensive model in interventional studies is suggested. These determinants should be considered in devel-
oping interventional programs to improve adherence.1. Introduction
Diabetes directly caused 1.6 million deaths in 2015 [1,2]; and it is
estimated that more than 690 million people will have diabetes by 2045
[3]. In Iran, 11% of people over 25 years old have type 2 diabetes [3].
Diabetes is a main cause of premature death, blindness, kidney failure,
heart attack, stroke and lower limb amputation [1].
Low adherence to medication is one of the important common
problems in patients. Many patients face difficulties in following treat-
ment recommendations [4]. Evidence shows that adherence to oral hy-
poglycemic agents (OHAs) in both type 1 and type 2 diabetes ranges from
36% to 93%; and adherence to insulin is almost 63% [5]. Non-adherent
patients are at high risk of expanding complications that affect their
health condition and quality of life [6]. Patients' adherence toakibazadeh).
6 May 2020; Accepted 9 July 2
is an open access article under tmedications is a crucial and important factor for preventing serious
complications and decreasing the health care costs [7].
Medication adherence is defined as “voluntary cooperation of the
patient in taking drugs or medicine as prescribed. This includes timing,
dosage, and frequency” [8]. Patients with diabetes often face several
complications in entirely adhering to their prescribed medication regi-
mens. Reasons of non-adherence include demographic factors,
disease-related factors (such as disease duration, occupation, and moni-
toring), and medication-related factors (such as side effects, complicacy
of the regimen, and type of medication) [9,10,11]. The reasons of
medication non-adherent are not completely known. A study conducted
in Shiraz, Iran in 2017 investigated the factors affecting insulin compli-
ance among 457 patients with Type 2 Diabetes. Reasons of insulin
non-adherence were insurance coverage issues, illiteracy, and020
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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injection [12].
Studies have showed that patients should be categorized according to
their level of preparation to pursue health recommendations [4].
Theories of health behavior change are needed to determine,
describe, and effectively promote self-regulation of individuals and to
optimize treatment [13]. In recent years, some theoretical determinants
of medication adherence have been introduced through well-designed
theories and models. Health action process approach (HAPA) is one of
the most known and helpful ones to identify effective cognitive factors
in adherence. HAPA is an open framework of various motivational and
volitional constructs that are assumed to explain and predict individual
changes in health behaviors [14]. According to the HAPA, the adoption,
initiation, and maintenance of health behaviors should be assumed as a
structured process including a motivation phase and a volition phase
[15]. Motivation phase includes the intention foundation and the latter
phase mentions to planning, and action (initiative, maintenance, re-
covery) [15]. According to this model, there is a distinction between
pre-intentional motivation phase that leads to a behavioral intention,
and post-intentional volition phase that leads to the real health
behavior [16]. In the motivation phase, a person extends an intention to
behavior. Intention is person's motivation towards a target behavior
[15]. In this phase, task self-efficacy is ones belief in his/her ability to
perform a desired behavior [16]. It can help form a behavioral inten-
tion. After the intention is formed, the individual enters the volitional
phase. In this phase, good intention should be converted to accurate
instructions on how to do the desired action [16]. This change must be
planned, initiated, and maintained, and relapses have to be managed.
An action plan usually is concrete ideas about “when,” “where,” and
“how” to act for the purpose of the formed intention [15]. But action
planning is strongly influenced by self-efficacy. Task self-efficacy in the
motivational phase is different from volitional self-efficacy (e.g., coping
self-efficacy, recovery self-efficacy) [17]. Optimistic beliefs about one's
capability to overcome barriers that arise during the maintenance
process is called coping self-efficacy [15]. Recovery self-efficacy de-
scribes person's notion to get back on route after a setback or failure
[15]. Coping planning is a self-regulatory strategy with a focus on
barriers [18]. Perceived barriers is potential negative aspects of a
particular health behavior (e.g., side effects, painful, difficult) [19].
Acceptance of individual susceptibility to a condition also believed to
be serious is called perceived benefits [19]. Different factors influence
the adherence medication; and HAPA inventory includes various fac-
tors, especially types of self-efficacy at different stages of health
behavior change too.
It became necessary to highlight the recent status of adherence to
diabetic medications among type 2 diabetes patients in Tehran and show
the cultural differences within the same Iranian population. So, the aim
of this study was to identify determinants of medication adherence based
on the HAPA among patients with type 2 diabetes attending to the South
Tehran health centers.
2. Materials and methods
2.1. Research design and participants
This cross-sectional study carried out at South Tehran Health Centers,
affiliated to Tehran University of Medical Sciences from June to
December 2018. We used multi state cluster sampling (assuming the
centers as cluster). In this sampling the sample size in each center was
proportional to their population coverage. Sample selection within each
centers was performed using consecutive sampling in random days until
the required sample size is achieved in that center.
The inclusion criteria were: being diagnosed with type 2 diabetes for
more than six months, absence of any mental, visual, and learning dis-
abilities (according to the clinical diagnosis by physician), and having
consent to participate in the study. The exclusion criteria were other2
types of diabetes including type 1 diabetes or gestational diabetes; and
having acute mental and disabling disorders.
2.2. Data collection tools and scoring
Demographic characteristics including participants' age, marital sta-
tus, job status, income, gender, duration of disease, and education level
were measured. A HAPA self-structured questionnaire consisted of eight
sections and 38 items were developed (Appendix 1) based on a literature
[20,21,22,23]. The sections consisted of: (a) Intention to medications
adherence (2 items) (e.g., “During the next months, I intend to take my
medications/inject insulin as prescribed.”), measured using
seven-interval Likert scales, ranging from 1 (strongly disagree) to 7
(strongly agree) with higher scores indicating high level of intention; (b)
Task self-efficacy of diabetes medications adherence (6 items) (e.g., “I
can take my drugs or medicine/inject my insulin as prescribed even if my
surroundings do not remind me to take my medication or inject my in-
sulin.”), rated on a 4-point scale ranging from 1 (not at all true) to 4
(exactly true); (c) Copping self-efficacy (7 items) (e.g., “I can keep taking
my medications/injecting my insulin as prescribed even if I am tired.”),
scores for benefits item ranging from 1 (not at all true) to 4 (exactly true),
with higher scores determining better condition; (d) Recovery
self-efficacy (3 items) (e.g., “I am sure I can retake my medications/inject
my insulin as prescribed even if I have paused for several times.”), rated
on a 4- point scale ranging from 1 (not at all true) to 4 (exactly true); (e)
Action planning (2 items) (e.g., “I already have concrete plans how to
take my medications or inject my insulin on time.”), rated on a 4- point
scale ranging from 1 (not at all true) to 4 (exactly true); (f) Copping
planning (6 items) (e.g., “I already have concrete plans how to deal with
relapses not to take my medications/not to inject my insulin as pre-
scribed.”), rated on a 4- point scale ranging from 1 (not at all true) to 4
(exactly true), scores were recoded to show a better condition; (g) Bar-
riers to adherence (9 items) (e.g., “It is difficult for me to take medica-
tions or inject insulin on time.”), scores for this item ranged from 1
(strongly disagree) to 7 (strongly agree), higher scores represented a high
level of barriers; (h) Resources and benefits (3 items) (e.g., “My blood
glucose is regulated by taking my medications/or injecting my insulin as
prescribed. ”).
We transformed the scores of each item to 0–100 using the following
formula:
The new score of item ¼ 100 * (Score of item – Minimum possible
score)/Range of possible scores. Then we calculated the section score as
the average of item scores in that section for each subject.
2.2.1. Face validity
First, in order to confirm difficulty, proportionality and ambiguity of
the items, the HAPA inventory was distributed to 20 type 2 diabetes
patients (10 males and 10 females) for purification purposes before
reliability testing.
2.2.2. Content validity
Content Validity Ratio (CVR) and Content Validity Index (CVI) have
been measured by means of a quantitative method in accordance to the
Lawshe table [24]. These two ways are applied to evaluate essentiality,
relevance, clarity and simplicity, respectively. We asked 10 experts in the
fields of health education and promotion, biostatistics and endocrinology
to complete the items. The CVI>0.9 and CVR>0.8 were computed. The
test-retest reliability of each scale has been determined.
2.2.3. Reliability
The Cronbach alpha, as an internal consistency indicator, were
examined to estimate true score variance with a 95% confidence interval.
The cut point of 0.70 was set for Cronbach alpha to detect acceptable
items for the new scales. The questionnaire was completed by 20 patients
after two weeks to calculate test-retest reliabilities. Total scale scores
from the first and second interview were put into the analysis. Then, the
S. Ranjbaran et al. Heliyon 6 (2020) e04442test-retest reliability of each scale was determined. The Cronbach's alpha
for the HAPA-based questionnaire was more than 0.7 and ICC1 was more
than 0.81.
The patients' adherence to medication regimen was measured using
the MMAS-8-Item [25]. Each item in Morisky questionnaire measures a
specific medication-taking behavior. Responds categories were yes/no
for each item and a 5-point Likert response for the last item [25]. The
correlation coefficient was calculated by Negarandeh (r ¼ 0.8) and the
Chronbach's alphas was more than 0.7 [26]. All questionnaires were
completed by one of the researchers through face-to-face interviews with
the patients.
2.3. Ethics statement
The Ethics Committee of Tehran University of Medical Sciences
(code: IR.TUMS.SPH.REC.1396.4200) approved the study. Before
enlistment in the study, the participants received a complete explanation
of the plan and objectives of the study and those willing to participate
provided written informed consent.
2.4. Statistical analysis
We analyzed the associations between HAPA constructs and medi-
cation adherence behavior using the Linear Regression test. We used the
chi-square test (for nominal variables which have assumption of this
test), Fisher exact test (for nominal variables which could not pass the
assumption of chi-square test) and Mann-Whitney test (for ordinal vari-
ables) to evaluate significant difference between medication adherence
status by the demographic variables. All statistical tests were assessed
using SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for Windows,
Version 25.0. Armonk, NY: IBM Corp.). P-value less than 0.05 was
considered statistically significant.
Since we had eight sections (latent variables) and 38 items to calcu-
late, we had 46 variable totally considering 10 samples for each item. So
we needed 460 samples, however as we performed cluster sampling we




A total of 734 participants met the criteria for inclusion. Table 1 de-
scribes the demographic characteristics of the participants. Most of the
participants (82.3%) met the criteria for non-adherence. Most of them
(68.4%) were female, 36.9% had primary education, 73.6% had low
income (10,000,000 to 20,000,000 Rls), and 81.5% were married. There
was a significant association between the medication adherence behavior
with gender (p ¼ 0.036); men were more non-adherent in comparison to
women.
3.2. Association between medication adherence and the HAPA constructs
Table 2 presents the linear regression analysis correlations between
the medication adherence behavior and the HAPA constructs. Statisti-
cally significant correlations were found between the medication
adherence behavior and HAPA constructs, except for recovery self-
efficacy, action planning, barriers and resources. Patients who had
more intention to medication adherence (β ¼ 0.172, 95% CI ¼ 0.07,
0.22), had higher level of task self-efficacy (β ¼ 0.172, 95% CI ¼ 0.03,
0.27), higher coping self-efficacy (β ¼ - 0.244, 95% CI ¼ - 0.33, - 0.08)
and higher coping planning (β ¼ 0.6, 95% CI ¼ 0.4, 0.62) tend to more
likely engage in medication adherence behavior. Table 3 shows the1 Intra Class Correlation.
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patient responses to the medication adherence questions. Feeling hassled
about sticking to the anti diabetic treatment plan highlighted by 97.6% of
patients. 94.6% of patients forgot to take their diabetes medications.
91.8% of patients' answers to the question “Did you take your anti-
diabetic medicines yesterday?” were “no”. When patients felt like their
diabetes was under control, they stopped taking their medications.
4. Discussion
Our study showed that most of participants were non-adherent to
medication. Similar findings have been reported from other studies in
Mexico (82.8%) [27]. In a study conducted by Alatawi et al., 60% of
patients did not take the number of prescribed doses per day; and up to
40% reported low adherence [28]. Many patients with diabetes are poor
compliers with treatment, including both OHAs and insulin [5]. Prob-
lems with poor adherence may deteriorate the burden of diabetes and
end up with poor health outcomes, lower quality of life, and increased
health care costs. So, it is important to investigate the reasons behind the
issue.
Our study showed that there was a significant relationship between
the medication adherence with gender. This was consistent with the
findings reported by Alatewi in Saudi Arabia [28], Raum and et al. [29],
and Elsous and et al. [30], But Jarab presented that there was no sig-
nificant relationship between gender and medication non-adherence in
patients with type 2 diabetes [31]. This difference in results of studies
may be due to diversity in culture. According to these findings, the
gender difference should be considered in order to improve the medi-
cation adherence.
Intention, task self-efficacy, coping planning and copping self-efficacy
predicted medication adherence behavior significantly; which would
corroborate previous research findings. Intention is an important factor
in adopting healthy behaviors. Nevertheless, good intentions do not
necessarily guarantee corresponding actions. Therefore, the other factors
are determinant in medication adherence behavior. Individuals would
fail to adopt, initiate, and maintain a planned action when they do not
believe in their own capability to do it [15]. Trevisan's study showed that
using behavioral strategies, including action planning and coping plan-
ning helped to improve adherence to medication adherence [32].
Self-efficacy is needed all over the entire behavior change process.
Because different challenges occur as people progress from one phase to
the next, specific self-efficacy is required [33] such as task self-efficacy
and coping self-efficacy. It is necessary to increase self-efficacy in these
patients. When setbacks occur, individuals with high coping self-efficacy
recover more quickly and maintain commitment to their goals [22]. In
coping planning, people should be able to imagine scenarios that they
barricade to do their intended behavior and they design one or more
plans to cope with these conditions and obstacles [34]. Because planning
facilitates the transition from intention to behavior [33]. This shows
coping planning can play key role in adherence to medication behavior in
patients with Type 2 diabetes. Purpose of the interventions should be
coping planning and coping self-efficacy for patients who are in the
volitional phase. The results pointed to the effective role self-regulatory
strategies (such as planning) in turning goals into action [35]. It is
essential to attend this factor in healthy interventions by health educa-
tors. In one study low adherence was associated with patients who are
not participated in the decision-making process or do not have an un-
derstanding of the problem or treatment, and creating confidence [36].
To promote medication adherence in patients with type 2 diabetes,
providing information to patients about feasibility issues concerning
medication intake and increasing self-efficacy is beneficial [37]. Our
study showed that most patients forgot to take their diabetes medica-
tions. Feeling hassled about anti diabetic treatment plan and forgetful-
ness were the most common reasons for non-medication adherence. This
confirms that feeling hassled from treatment programs is a common
problem in chronic diseases such as diabetes; and this highlights the
importance of self-efficacy beliefs in these groups of patients. Patients'
Table 1. Characteristics of the participants (n ¼ 734).





Level of Education Illiterate 51 19% 218 81% 0.464*
Elementary 36 13.3% 235 86.7%
Middle school 17 17.9% 78 82.1%
High school 21 25.6% 61 74.4%
University degree 5 29.4% 12 70.6%
Age (Yrs)  45 9 20.9% 34 79.1% 0.899*
46–55 29 18.8% 125 81.2%
56–65 43 14.6% 252 85.4%
66–75 43 22.6% 147 77.4%
76þ 6 11.5% 46 88.5%
Gender (n) Female 99 19.7% 403 80.3% 0.036**
Male 31 13.4% 201 86.6%
Marital status (n) Married 104 17.4% 494 82.6% 0.890**
Single 2 18.2% 9 81.8%
Died 24 19.2% 101 80.8%
Job (n) Unemployment 0 0 8 100% 0.147***
Retired 22 12.6% 152 87.4%
Clerk 5 21.7% 18 78.3%
Free job 11 15.7% 59 84.3%
Housewife 92 20% 367 80%
Income (Rls) ˂500,000 8 12.1% 58 87.9% 0.103*
500,000–1000,000 19 18.1% 86 81.9%
1000,000–2000,000 94 17.4% 446 82.6%
>2000,000 9 39.1% 14 60.9%
Duration of diabetes (Yrs) 5 36 14.8% 208 85.2% 0.121*
5.01–10 36 18% 164 82%
10.01–15 24 20.3% 94 79.7%
15.01–20 21 18.6% 92 81.4%
20.01þ 13 22% 46 78%
Medications (n) Tablet 80 16.3% 412 83.7% 0.068**
Tablet & Insulin 26 17.4% 123 82.6%
Insulin 24 26.4% 67 73.6%
p < 0.05, * Mann-Whitney Test, **Pearson Chi-Square Test, ***Fisher's Exact Test.
Table 2. Linear Regression analysis to predict medication adherence behavior.





Constant 1.94 4.92 0.693
Intention 0.150 0.03 0.000 0.172 0.076 0.223
Task Self -efficacy 0.157 0.06 0.01 0.172 0.037 0.276
Copping Self -efficacy -0.211 0.06 0.001 - 0.244 -0.334 -0.089
Recovery Self- efficacy -0.099 0.05 0.055 - 0.133 -0.199 0.002
Action Planning -0.015 0.05 0.768 - 0.020 -0.115 0.085
Copping Planning 0.516 0.05 0.000 0.6 0.407 0.624
Barriers 0.008 0.04 0.842 0.007 -0.072 0.088
Resources and benefits -0.007 0.03 0.848 -0.006 -0.079 0.065
(R2 ¼ 0.34, F ¼ 41.48, p < 0.05).
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forgetfulness [38]. Guenette and et al., presented adherence to medica-
tion associated with having signs to remember to take them [39], Gou-
veia also reported that forgetting to take medication in patient with type
2 diabetes was not a barrier of adherence because it was perceived as an
unaware behavior by patients; however, if this behavior was repeated it4
could be on purpose. At this stage, patient paid little attention to take
their medications [40]. Most of the patients had taken their anti-diabetic
medicines the previous day. Hence, it is important to identify the moti-
vational and voluntary reasons of this behavior in these patients. About
half of the patients who felt like their diabetes was under control, stopped
taking their medications. This was consistent with the findings reported
Table 3. Patient responses to the medication adherence questionnaire (n ¼ 734).
Questions Responses n (%)
Yes No
Do you sometimes forget to take your diabetes pills/injections? 694 (94.6) 40 (5.4)
People sometimes miss taking their medications for reasons other
than forgetting. Thinking over the past 2 weeks, were there any
days when you did not take your diabetes medicine?
377 (51.4) 357 (48.6)
Have you ever cut back or stopped taking your medication
without telling your doctor, because you felt worse when you
took it?
306 (41.7) 428 (58.3)
When you travel or leave home, do you sometimes forget to bring
along your diabetes medication?
508 (69.2) 226 (30.8)
Did you take your anti-diabetic medicines yesterday? 674 (91.8) 60 (8.2)
When you feel like your diabetes is under control, do you
sometimes stop taking your medicine?
321 (43.7) 413 (56.3)
Do you ever feel hassled about sticking to your anti diabetic
treatment plan?
717 (97.6) 17 (2.3)
How often do you have difficulty remembering to take all your
medications?
Never Rarely Sometimes Always
19 (2.6) 215 (29.3) 391 (53.3) 109 (14.9)
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control, they did not need to take medications [41]. Low perception of
susceptibility and severity of the disease can make low medication
adherence in these patients [42]. Considering these findings, it is
essential to pay more attention to patients with poor medication adher-
ence, especially women. This study identified the predictors of medica-
tion adherence among patient with type 2 diabetes that can inform
interventional studies in the area.
Like other cross-sectional studies, there are some limitations in our
study. We have to be careful about interpreting the associations and di-
rection of associations from a cross-sectional survey. Moreover, data
were collected via self-report questionnaires that can potentially cause
biases.4.1. Implications for practice and future research
Patients who fully adhere to their doctors' advice and treatment plan
have less complications. Our study showed that medication adherence is
low among our patients. The reasons behind the low adherence should be
investigated through future research studies; and identified reasons
should be considered to be resolved via well-designed health promotive
programs. In this study, we identified a series of cognitive factors that can
predict medication adherence. These cognitive factors that facilitate or
hinder medication adherence behavior and should be considered by the
diabetes program planners. Our study showed that intention, task self-
efficacy, coping planning and coping self-efficacy predict the medica-
tion adherence behavior among patients. Using related theory-driven and
evidence-based methods and practical applications to improve these
factors can help patients to more adhere to medication.
In this study, factors influencing medication adherence among pa-
tients with type 2 diabetes was identified according to HAPA. Data were
collected using face-to-face interviews, which helped us to gather valid
data from low literate patients. Most available studies have worked on
health behavior changes for the same time, regardless of the health
behavior models and or theories. This study identified the constructs of
HAPA that could help health program planners to develop interventions
that might be more effective in maintaining the interventions' effects.
5. Conclusion
We identified various cognitive factors influencing the adherence to
medication, especially the types of self-efficacy based on the HAPA
model. We found intention, task self-efficacy, coping planning and
coping self-efficacy as the most important determinants contributed to5
medication adherence among patients with type 2 diabetes. The HAPA
was found to be helpful in determining the predictors of medication
adherence among these patients. Designing interventional programs
aiming at promoting medication adherence level considering these de-
terminants are promising. Diabetes educators and healthcare providers
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